Welcome to our dedicated page for Utah Med Prods SEC filings (Ticker: UTMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for clarity on Utah Medical Products’ highly specialized business? Investors often start with where to find Utah Medical Products insider trading Form 4 transactions and end up digging through hundreds of pages about FDA clearances and manufacturing margins. This page brings everything together—Utah Medical Products SEC filings explained simply, one click away.
Use Stock Titan’s AI-powered summaries to cut through technical language. Whether you need the latest Utah Medical Products quarterly earnings report 10-Q filing to track neonatal device sales, or want Utah Medical Products Form 4 insider transactions real-time before market open, each document arrives seconds after EDGAR posts. Our engine highlights segment revenue swings, new product approvals and legal updates so you can focus on decisions, not page counts.
Wonder how leadership is aligned? The platform flags Utah Medical Products executive stock transactions Form 4 and cross-links them to compensation details in the Utah Medical Products proxy statement executive compensation. Need the bigger picture? The Utah Medical Products annual report 10-K simplified lays out gross-margin trends across disposable versus reusable lines, while the Utah Medical Products earnings report filing analysis spotlights R&D intensity. Unexpected news surfaces fast through our AI notes on Utah Medical Products 8-K material events explained. All filings—10-K, 10-Q, 8-K, S-8, plus every Form 4—stream into one dashboard, complete with plain-English takeaways, downloadable tables and historical comparisons. Understanding Utah Medical Products SEC documents with AI has never been so direct.
Paul O. Richins, a director of Utah Medical Products, sold 100 shares of the company's common stock on 08/25/2025 at $60.34 per share. After the sale he beneficially owns 21,136 shares indirectly, held across a family trust, a personal IRA, his spouse's IRA and his sons' accounts: 18,948 shares in the Richins Family Trust, 1,245 in his spouse's IRA, 443 by his sons and 500 in his own IRA. The Form 4 indicates the filing was made by one reporting person and is signed by Mr. Richins.
Brandes Investment Partners, L.P. reports beneficial ownership of 271,537 common shares of Utah Medical Products, representing 7.39% of the class as stated in Item 4. The filing shows Brandes holds shared voting and shared dispositive power over these shares and reports no sole voting or dispositive power, indicating it does not exercise unilateral control.
The statement is filed on Schedule 13G/A and classifies the reporting person as IA, PN (investment adviser/portfolio manager). The filer certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Utah Medical Products (UTMD) reported Q2 2025 net sales of $9,953 thousand, down 4.3% from $10,400 in Q2 2024, and first-half sales of $19,663 thousand, down 9.6% year-over-year. Gross profit fell to $5,595 thousand (56.2% margin) from $6,253 thousand (60.1%), driven by lower volumes, an unfavorable product mix in Ireland and reduced orders from former large OEM customer PendoTECH. Net income was $3,048 thousand in Q2 and $6,089 thousand for 1H 2025; diluted EPS were $0.94 and $1.86, respectively.
The company remains well capitalized with $82.2 million in cash and investments, no debt, ongoing dividends and opportunistic share repurchases (119,255 shares repurchased in 1H 2025 for $6.7 million). Management expects full-year PendoTECH sales to be about $2.0 million lower than 2024, is tracking adjusted EBITDA near targets, and highlights potential OUS tariff and distributor-timing risks that could affect 2H results.
FAQ
What is the current stock price of Utah Med Prods (UTMD)?
What is the market cap of Utah Med Prods (UTMD)?
